-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Tessera Therapeutics, a biotechnology company dedicated to pioneering new technologies in gene therapy, announced that it has received more than $300 million in Series C financing
Combined with the $230 million Series B round that closed in January 2021, the company has raised over $500 million in less than two years
And what Tessera is doing is doing something very different from most gene therapy companies -- curing disease by "writing" the code of life
What Tessera is doing is doing something very different from most gene therapy companies -- curing disease by "writing" the code of life
One class is based on RNA, which can "write" genetic information into the genome according to the RNA template
According to the press release, Tessera's new funding round will support the company's continued efforts to build its gene "writing" platform and advance multiple therapeutic programs into clinical development
They believe that genetic medicine will be the most important next era in medicine—providing the ability to cure genetic diseases, and even stop them one day in the future
Tessera's gene "writing" platform is charting an entirely new blueprint aimed at revolutionizing genetic medicine
Original in English: https:// href="https://" target="_blank">https:// References:
References:[1] Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform.
[1] Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform.